CIK: 0001792206 · Show all filings
Period: Q3 2022 (← Previous) (Next →)
Filing Date: Nov 14, 2022
Total Value ($000): $130,057 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | 1,258,243 | $19,805 | 15.2% | $19.56 | -19.4% | COM | 00461U105 |
| — | Theseus Pharmaceuticals, Inc. | 3,335,346 | $19,345 | 14.9% | $12.42 | — | COM | 88369M101 |
| HIMS | Hims & Hers Health, Inc. | 3,319,786 | $18,524 | 14.2% | $9.03 | -33.3% | COM CL A | 433000106 |
| — | Pardes Biosciences Inc | 9,400,515 | $17,391 | 13.4% | $16.37 | — | COM | 69945Q105 |
| — | Kinnate Biopharma Inc. | 875,001 | $10,456 | 8.0% | $39.78 | — | COM | 49705R105 |
| — | Somalogic, Inc. | 3,516,472 | $10,198 | 7.8% | $12.39 | — | COM CL A | 83444K105 |
| CMPX | Compass Therapeutics, Inc. | 4,400,000 | $10,032 | 7.7% | $3.29 | -15.8% | COM | 20454B104 |
| — | Adicet Bio, Inc. | 680,000 | $9,670 | 7.4% | $17.49 | — | COM | 007002108 |
| IVVD | Invivyd, Inc. | 1,431,826 | $4,482 | 3.4% | $34.15 | -88.3% | COM | 00534A102 |
| — | Gemini Therapeutics, Inc. | 2,435,125 | $3,994 | 3.1% | $13.55 | — | COM | 36870G105 |
| QSI | Quantum-Si Incorporated | 924,379 | $2,542 | 2.0% | $10.48 | -69.5% | COM CL A | 74765K105 |
| ENTA | Enanta Pharmaceuticals, Inc. | 42,250 | $2,192 | 1.7% | $65.07 | -10.2% | COM | 29251M106 |
| — | 23andMe Holding Co. | 406,913 | $1,164 | 0.9% | $11.69 | — | COM CL A | 90138Q108 |
| PHVS | Pharvaris N.V. | 34,142 | $262 | 0.2% | $31.46 | -50.4% | COM | N69605108 |